コンテンツへスキップ
Merck
  • Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction.

Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction.

Cancer research (2020-07-12)
Hanumantha Rao Madala, Iiro Taneli Helenius, Wen Zhou, Evanna Mills, Yiyun Zhang, Yan Liu, Ana M Metelo, Michelle L Kelley, Surendra Punganuru, Kyung Bo Kim, Benjamin Olenchock, Eugene Rhee, Andrew M Intlekofer, Othon Iliopoulos, Edward Chouchani, Jing-Ruey Joanna Yeh
要旨

Under conditions of inherent or induced mitochondrial dysfunction, cancer cells manifest overlapping metabolic phenotypes, suggesting that they may be targeted via a common approach. Here, we use multiple oxidative phosphorylation (OXPHOS)-competent and incompetent cancer cell pairs to demonstrate that treatment with α-ketoglutarate (aKG) esters elicits rapid death of OXPHOS-deficient cancer cells by elevating intracellular aKG concentrations, thereby sequestering nitrogen from aspartate through glutamic-oxaloacetic transaminase 1 (GOT1). Exhaustion of aspartate in these cells resulted in immediate depletion of adenylates, which plays a central role in mediating mTOR inactivation and inhibition of glycolysis. aKG esters also conferred cytotoxicity in a variety of cancer types if their cell respiration was obstructed by hypoxia or by chemical inhibition of the electron transport chain (ETC), both of which are known to increase aspartate and GOT1 dependencies. Furthermore, preclinical mouse studies suggested that cell-permeable aKG displays a good biosafety profile, eliminates aspartate only in OXPHOS-incompetent tumors, and prevents their growth and metastasis. This study reveals a novel cytotoxic mechanism for the metabolite aKG and identifies cell-permeable aKG, either by itself or in combination with ETC inhibitors, as a potential anticancer approach. SIGNIFICANCE: These findings demonstrate that OXPHOS deficiency caused by either hypoxia or mutations, which can significantly increase cancer virulence, renders tumors sensitive to aKG esters by targeting their dependence upon GOT1 for aspartate synthesis. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/17/3492/F1.large.jpg.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
アンチマイシンA 放線菌由来
Sigma-Aldrich
アデノシン 5'-三リン酸 二ナトリウム塩 水和物, BioXtra, ≥99% (HPLC), from microbial
Sigma-Aldrich
ロテノン, ≥95%
Sigma-Aldrich
アデノシン 5′-二リン酸 一カリウム塩 二水和物, bacterial, ≥95%, powder
Sigma-Aldrich
アデニン, BioReagent, suitable for cell culture
Sigma-Aldrich
ジメチル2-オキソグルタル酸, 96%
Sigma-Aldrich
O-(カルボキシメチル)ヒドロキシルアミン ヘミ塩酸塩, 98%
Sigma-Aldrich
ブロモピルビン酸, ≥98.0%
Sigma-Aldrich
β,γ-メチレンアデノシン5′-三リン酸 二ナトリウム塩, ≥95%, solid
Sigma-Aldrich
ETaKG, ≥95% (HPLC)
Sigma-Aldrich
diethyl 2-oxoglutarate, AldrichCPR